Behavioral consequences of ovarian atrophy and estrogen replacement in the APPswe mouse

Mari S. Golub, Stacey L. Germann, Mary Mercer, Marcia N. Gordon, David G. Morgan, Loretta P. Mayer, Patricia B Hoyer

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Cognitive performance was evaluated in a longitudinal study of APPswe2576 transgenic mice (APP) and a wildtype (WT) comparison group. Subgroups of the APP mice were treated with the ovarian toxicant 4-vinylcyclo-hexene diepoxide (VCD) at 60-75 days of age to induce ovarian atrophy and/or given estrogen (estradiol, 4 μg/day) continuously by pellet from 76 days of age. APP mice had a generally poorer radial maze performance than WT at 4.5, 7.5, 10.5 and 15 months of age. In separate tests, APP mice had a slight motor impairment, higher incidence of homecage stereotypy, hyperactivity in an open field and reduced object exploration relative to the WT group. Ovarian atrophy led to better maze performance at 7.5 months. The effect of estrogen on maze performance with aging could not be effectively evaluated due to poor survival (30%) of these mice. No effects of ovarian atrophy or estrogen treatment were identified for amyloid-beta accumulation or plaque formation at 15 months. Long-term longitudinal studies in animal models are needed to explore the consequences of menopause and hormone replacement on Alzheimer's disease, but they are complicated by considerations of survival, pre-aging deficits, testing experience and selection of appropriate estrogen treatment levels.

Original languageEnglish (US)
Pages (from-to)1512-1523
Number of pages12
JournalNeurobiology of Aging
Volume29
Issue number10
DOIs
StatePublished - Oct 2008

Fingerprint

Estrogen Replacement Therapy
Atrophy
Estrogens
Longitudinal Studies
Menopause
Amyloid
Transgenic Mice
Estradiol
Alzheimer Disease
Animal Models
Hormones
Incidence
Therapeutics

Keywords

  • Aging
  • Alzheimer's disease
  • Estradiol
  • Menopause
  • Radial arm maze
  • Transgenic mouse

ASJC Scopus subject areas

  • Clinical Neurology
  • Biological Psychiatry
  • Developmental Neuroscience
  • Neurology
  • Psychology(all)

Cite this

Behavioral consequences of ovarian atrophy and estrogen replacement in the APPswe mouse. / Golub, Mari S.; Germann, Stacey L.; Mercer, Mary; Gordon, Marcia N.; Morgan, David G.; Mayer, Loretta P.; Hoyer, Patricia B.

In: Neurobiology of Aging, Vol. 29, No. 10, 10.2008, p. 1512-1523.

Research output: Contribution to journalArticle

Golub, Mari S. ; Germann, Stacey L. ; Mercer, Mary ; Gordon, Marcia N. ; Morgan, David G. ; Mayer, Loretta P. ; Hoyer, Patricia B. / Behavioral consequences of ovarian atrophy and estrogen replacement in the APPswe mouse. In: Neurobiology of Aging. 2008 ; Vol. 29, No. 10. pp. 1512-1523.
@article{6498b8c7866440b6895e939f2d211422,
title = "Behavioral consequences of ovarian atrophy and estrogen replacement in the APPswe mouse",
abstract = "Cognitive performance was evaluated in a longitudinal study of APPswe2576 transgenic mice (APP) and a wildtype (WT) comparison group. Subgroups of the APP mice were treated with the ovarian toxicant 4-vinylcyclo-hexene diepoxide (VCD) at 60-75 days of age to induce ovarian atrophy and/or given estrogen (estradiol, 4 μg/day) continuously by pellet from 76 days of age. APP mice had a generally poorer radial maze performance than WT at 4.5, 7.5, 10.5 and 15 months of age. In separate tests, APP mice had a slight motor impairment, higher incidence of homecage stereotypy, hyperactivity in an open field and reduced object exploration relative to the WT group. Ovarian atrophy led to better maze performance at 7.5 months. The effect of estrogen on maze performance with aging could not be effectively evaluated due to poor survival (30{\%}) of these mice. No effects of ovarian atrophy or estrogen treatment were identified for amyloid-beta accumulation or plaque formation at 15 months. Long-term longitudinal studies in animal models are needed to explore the consequences of menopause and hormone replacement on Alzheimer's disease, but they are complicated by considerations of survival, pre-aging deficits, testing experience and selection of appropriate estrogen treatment levels.",
keywords = "Aging, Alzheimer's disease, Estradiol, Menopause, Radial arm maze, Transgenic mouse",
author = "Golub, {Mari S.} and Germann, {Stacey L.} and Mary Mercer and Gordon, {Marcia N.} and Morgan, {David G.} and Mayer, {Loretta P.} and Hoyer, {Patricia B}",
year = "2008",
month = "10",
doi = "10.1016/j.neurobiolaging.2007.03.015",
language = "English (US)",
volume = "29",
pages = "1512--1523",
journal = "Neurobiology of Aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - Behavioral consequences of ovarian atrophy and estrogen replacement in the APPswe mouse

AU - Golub, Mari S.

AU - Germann, Stacey L.

AU - Mercer, Mary

AU - Gordon, Marcia N.

AU - Morgan, David G.

AU - Mayer, Loretta P.

AU - Hoyer, Patricia B

PY - 2008/10

Y1 - 2008/10

N2 - Cognitive performance was evaluated in a longitudinal study of APPswe2576 transgenic mice (APP) and a wildtype (WT) comparison group. Subgroups of the APP mice were treated with the ovarian toxicant 4-vinylcyclo-hexene diepoxide (VCD) at 60-75 days of age to induce ovarian atrophy and/or given estrogen (estradiol, 4 μg/day) continuously by pellet from 76 days of age. APP mice had a generally poorer radial maze performance than WT at 4.5, 7.5, 10.5 and 15 months of age. In separate tests, APP mice had a slight motor impairment, higher incidence of homecage stereotypy, hyperactivity in an open field and reduced object exploration relative to the WT group. Ovarian atrophy led to better maze performance at 7.5 months. The effect of estrogen on maze performance with aging could not be effectively evaluated due to poor survival (30%) of these mice. No effects of ovarian atrophy or estrogen treatment were identified for amyloid-beta accumulation or plaque formation at 15 months. Long-term longitudinal studies in animal models are needed to explore the consequences of menopause and hormone replacement on Alzheimer's disease, but they are complicated by considerations of survival, pre-aging deficits, testing experience and selection of appropriate estrogen treatment levels.

AB - Cognitive performance was evaluated in a longitudinal study of APPswe2576 transgenic mice (APP) and a wildtype (WT) comparison group. Subgroups of the APP mice were treated with the ovarian toxicant 4-vinylcyclo-hexene diepoxide (VCD) at 60-75 days of age to induce ovarian atrophy and/or given estrogen (estradiol, 4 μg/day) continuously by pellet from 76 days of age. APP mice had a generally poorer radial maze performance than WT at 4.5, 7.5, 10.5 and 15 months of age. In separate tests, APP mice had a slight motor impairment, higher incidence of homecage stereotypy, hyperactivity in an open field and reduced object exploration relative to the WT group. Ovarian atrophy led to better maze performance at 7.5 months. The effect of estrogen on maze performance with aging could not be effectively evaluated due to poor survival (30%) of these mice. No effects of ovarian atrophy or estrogen treatment were identified for amyloid-beta accumulation or plaque formation at 15 months. Long-term longitudinal studies in animal models are needed to explore the consequences of menopause and hormone replacement on Alzheimer's disease, but they are complicated by considerations of survival, pre-aging deficits, testing experience and selection of appropriate estrogen treatment levels.

KW - Aging

KW - Alzheimer's disease

KW - Estradiol

KW - Menopause

KW - Radial arm maze

KW - Transgenic mouse

UR - http://www.scopus.com/inward/record.url?scp=49149119801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49149119801&partnerID=8YFLogxK

U2 - 10.1016/j.neurobiolaging.2007.03.015

DO - 10.1016/j.neurobiolaging.2007.03.015

M3 - Article

C2 - 17451844

AN - SCOPUS:49149119801

VL - 29

SP - 1512

EP - 1523

JO - Neurobiology of Aging

JF - Neurobiology of Aging

SN - 0197-4580

IS - 10

ER -